Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

BACKGROUND: The third-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated EGFR-mutated non-small cell lung cancer (NSCLC) who acquire the T790M resistance mutation. However, no standard treatmen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Target Oncol
Hauptverfasser: Mu, Yuxin, Hao, Xuezhi, Yang, Ke, Ma, Di, Wang, Shouzheng, Xu, Ziyi, Li, Junling, Xing, Puyuan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2019
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6602986/
https://ncbi.nlm.nih.gov/pubmed/31124059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-019-00644-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge